Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Valentine Sergeev"'
Autor:
Pearce G. Wilcox, Frank Y Chou, Valentine Sergeev, Bradley S. Quon, Grace Y. Lam, Christopher Michael Hamilton
Publikováno v:
Annals of the American Thoracic Society
The effects of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators on lung function, pulmonary exacerbations, and quality of life have been well documented. However, CF is a multiorgan disease, and therefore an evidence base is
Autor:
Victoria Su, Jane Kerr, Valentine Sergeev, Sameer Desai, Pearce G. Wilcox, Bradley S. Quon, Eri Flores
Publikováno v:
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 4:174-179
Lumacaftor-ivacaftor (LUM-IVA) was approved for use in Canada in January 2016. Observational studies have reported a higher incidence of treatment-emergent adverse events (AEs) leading to treatment...
Autor:
ZhaoKai Pang, Ravichandra Venkateshappa, Dominic G. Whittaker, Gary R. Mirams, Valentine Sergeev, Glen F. Tibbits, Thomas W. Claydon, Jacob M Kemp, Raj Johal
Publikováno v:
The Journal of General Physiology
Kemp et al. show that the hERG channel activator RPR260243 restores the repolarizing current of a mutant variant of the channel associated with LQTS2 with little effect on its resurgent current. This drug represents a therapeutic opportunity for the
Autor:
James Young, Samrat Thouta, Yen May Cheng, Valentine Sergeev, Yu Patrick Shi, Thomas W. Claydon, Christina M. Hull
Publikováno v:
Biophysical Journal. 112:300-312
Slow deactivation of hERG channels is critical for preventing cardiac arrhythmia yet the mechanistic basis for the slow gating transition is unclear. Here, we characterized the temporal sequence of events leading to voltage sensor stabilization upon
Autor:
Shubhayan Sanatani, Thomas M. Roston, Frances Perry, Glen F. Tibbits, Valentine Sergeev, Thomas W. Claydon
Publikováno v:
Forensic science international. 284
Long QT syndrome (LQTS) is the most common cardiac ion channelopathy and has been found to be responsible for approximately 10% of sudden infant death syndrome (SIDS) cases. Despite increasing use of broad panels and now whole exome sequencing (WES)